Does the dose of iodine-131 influence the incidence of Graves’ ophthalmopathy?

BackgroundRadioactive iodine-131 (RAI) is an established treatment for patients with Graves’ hyperthyroidism. RAI is reported to be associated with a 20–30% incidence of development or exacerbation of Graves’ ophthalmopathy (GO). This study compares the progression of GO in patients who had evidence